Trial Profile
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, Recentin), in Patients With Advanced Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Rifampicin
- Indications Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 09 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 04 Jun 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 07 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.